Basic Information
| LncRNA/CircRNA Name | TTN-AS1 |
| Synonyms | NA |
| Region | GRCh38_2:178521183-178779963 |
| Ensemble | ENSG00000237298 |
| Refseq | NR_038272 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cervical cancer |
| ICD-0-3 | C53 |
| Methods | qPCR, Western blot, Luciferase assay, RIP |
| Sample | cervical cancer tissues, cell lines (SiHa, HeLa, C33a, Me180, Ms751, Ect1/E6E7) |
| Expression Pattern | up-regulated |
| Function Description | TTN-AS1 was substantially increased in CC tissues and cell lines, high expression of TTN-AS1 was correlated with advanced FIGO stage, poor differentiation, lymph node metastasis, and poor overall survival of CC patients. Function assays showed that TTN-AS1 inhibition decreased the proliferation and invasion of CC cells both in vitro and in vivo. Mechanistically, we revealed that TTN-AS1 could positively modulate E2F3 expression via sponging miR-573 in CC cells. LncRNA TTN-AS1 inhibition decreased CC cells proliferation, invasion, and EMT in vitro. |
| Pubmed ID | 30135013 |
| Year | 2018 |
| Title | Long non-coding RNA TTN-AS1 promotes cell growth and metastasis in cervical cancer via miR-573/E2F3. |
External Links
| Links for TTN-AS1 | GenBank HGNC NONCODE |
| Links for cervical cancer | OMIM COSMIC |